Blueprint Medicines (BPMC) Tops Q4 EPS by 9c

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.53), $0.09 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $34.1 million versus the consensus estimate of $29.24 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Carnival shares drop despite earnings beat on weak guidance
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)